Figure 1: Study attrition diagram

Experimental design
Conclusions related to the questions
Prevalence and Incidence of Neurocognitive dysfunction
Other conclusions
Maerzec et al., 2015 [12]
Prospective study
ACS, n=238
To describe the prevalence of neurocognitive dysfunction and health literacy in ACS patients
52% of participants had mild neurocognitive disorder and 14.8% had dementia
Prevalence: 66.8%
Neurocognitive dysfunction and poor health literacy are common in ACS patients. Mild neurocognitive disorder was associated to medication nonadherence
Mixon et al., 2014 [13]
Prospective study

ACS; n=333;
HF, n=99;

ACS and HF=39.
To analyse the association of patient and medication-related factors with post-discharge medication errors.
7,4% of the total sample had deficitary general neurocognitve functioning
Prevalence: 10.51%
51% of the patients with ACS and HF had at least one discordant medication after discharge; worse cognitive function was associated to higher odds of misunderstanding in frequency of medication.
Volonghi et al., 2013[14]
Longitudinal study
ACS, n=216; TIA, n= 182; Minor stroke, n=216
To study the neurocognitive outcomes 1 and 5 years after ACS versus TIA and minor stroke.
9% of ACS patients presented neurocognitive dysfunction at 1 year even when compared to TIA and minor stroke patients. 5 years after the ACS, 10.2% to 63% showed deficitary general neurocognitive functioning
Prevalence at 1 year: 9% Prevalence at 5 years: 10.2% determined by MMSE and 63% determined by MoCA Incidence rate (5 year period): 0.0277 cases per person-year
Risk of cognitive impairment after ACS is similar to minor stroke and higher than TIA with implications for consent and adherence to medication. Cognitive performance in ACS is suggestive of degenerative brain pathology
Bernard et al., 2015 [15]
Longitudinal study
ACS, n=33
To investigate the cerebral anatomo-functional substratum of executive dysfunction
At baseline, 36.1% of patients presented impaired executive function. At 6 months, 24.2% were classified as “impaired”, 30.3% as “transient impaired” and 45.5% as “cognitively normal”
Prevalence at baseline: 36.1% Prevalence at 6 months: 24.2% Incidence rate (6 month period): 0.416 cases per person-month
Executive dysfunction is associated to functional but no structural characteristics, particularly to an increased functional connectivity

ACS: Acute Coronary Syndrome; TIA: Transient Ischemic Attack; HF: Heart Failure; MMSE: Mini Mental State examination; MoCA: Montreal Cognitive Assessment
Table 1: Summary of the selected studies